Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TirbAKare: Tirbanibulin in Actinic Keratosis
NCT06135415Phase 3Completed
- Sponsor
- Almirall
- Start
- Dec 2023
- Primary completion
- Apr 2025
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 3, randomised, double-blind trial in actinic keratosis (AK) comparing Tirbanibulin 10 mg/g with Vehicle ointment (2 arms). Primary endpoint: Percent Change From Baseline in Lesion Count at Day 57. Started Dec 2023; status: completed.
02
Drugs
tirbanibulin
03
Conditions
actinic keratosis (AK)
Beyond the preview
Go deeper on NCT06135415.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06135415.